BLA 125,422 Submission Date(s): December 18, 2013
Brand Name Jetrea
Generic Name Ocriplasmin
Reviewer Yoriko Harigaya, Pharm.D.
Team Leader Philip M. Colangelo, Pharm.D., Ph.D.
OCP Division DCP IV
OND Division DTOP
Sponsor ThromboGenics
Submission Type (b)(4) Supplement – 25)
Formulation; Strength(s) Solution for intravitreal injection;
Ocriplasmin (b)(4) of the diluted solution
Proosed Indications (b)(4)
Dosage and Administration Administer a single intravitreal injection (b)(4)

ThromboGenics has submitted BLA125,422/25 (b)(4) for Jetrea™ (ocriplasmin) Intravitreal Injection 2.5mg/mL for (b)(4). The proposed dosing regimen is (b)(4) given a single intravitreal injection (b)(4)

BLA125,422 ocriplasmin was granted marketing authorization approval by the Agency on 17 October, 2012 for the treatment of symptomatic vitreomacular adhesion in adults as a single dose intravitreal injection of 0.125 mg. Currently, the sponsor has submitted the results of a small exploratory pediatric study in support of the postmarketing requirements listed in the Jetrea approval letter of October 17, 2012 provided by the Agency.

There was no new Clinical Pharmacology information provided, and no revisions to the Clinical Pharmacology sections of the currently approved Jetrea labeling are needed. Therefore, no Clinical Pharmacology review is needed.
Yoriko Harigaya, Pharm.D.
Reviewer
Clinical Pharmacology
DCP4/OCP/OTS

Concurrence
Philip Colangelo, Pharm.D., Ph.D.
Team Leader
Clinical Pharmacology
DCP4/OCP/OTS
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

YORIKO HARIGAYA
05/15/2014

PHILIP M COLANGELO
05/15/2014